- Home
- HAFN vs JANX Comparison
HAFN vs JANX Comparison
Compare HAFN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- JANX
- Stock Information
- Founded
- HAFN 2012
- JANX 2017
- Country
- HAFN Bermuda
- JANX United States
- Employees
- HAFN N/A
- JANX N/A
- Industry
- HAFN
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- JANX Health Care
- Exchange
- HAFN Nasdaq
- JANX Nasdaq
- Market Cap
- HAFN 2.5B
- JANX 2.2B
- IPO Year
- HAFN N/A
- JANX 2021
- Fundamental
- Price
- HAFN $5.04
- JANX $36.01
- Analyst Decision
- HAFN Strong Buy
- JANX Strong Buy
- Analyst Count
- HAFN 2
- JANX 11
- Target Price
- HAFN $8.25
- JANX $83.09
- AVG Volume (30 Days)
- HAFN 2.4M
- JANX 852.9K
- Earning Date
- HAFN 02-27-2025
- JANX 03-07-2025
- Dividend Yield
- HAFN 27.15%
- JANX N/A
- EPS Growth
- HAFN N/A
- JANX N/A
- EPS
- HAFN 1.69
- JANX N/A
- Revenue
- HAFN $3,039,225,000.00
- JANX $13,049,000.00
- Revenue This Year
- HAFN N/A
- JANX $39.66
- Revenue Next Year
- HAFN N/A
- JANX N/A
- P/E Ratio
- HAFN $2.89
- JANX N/A
- Revenue Growth
- HAFN 15.24
- JANX 54.12
- 52 Week Low
- HAFN $4.99
- JANX $14.84
- 52 Week High
- HAFN $8.99
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- JANX 34.78
- Support Level
- HAFN N/A
- JANX $36.13
- Resistance Level
- HAFN N/A
- JANX $38.13
- Average True Range (ATR)
- HAFN 0.00
- JANX 2.52
- MACD
- HAFN 0.00
- JANX 0.08
- Stochastic Oscillator
- HAFN 0.00
- JANX 5.71
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.